ITEMS IN AFP WITH KEYWORD:
Pregabalin is safe and effective for the management of neuropathic pain associated with diabetic peripheral neuropathy. Drawbacks include the cost and the lack of studies demonstrating equivalence or superiority to other treatments. However, pregabalin’s ease of dosing titration, minimal drug intera...
Tight control of blood glucose levels and risk factors for cardiovascular disease (e.g., hypertension, hypercholesterolemia) can substantially reduce the incidence of microvascular and macrovascular complications from type 1 diabetes. Physicians play an important role in helping patients make essent...
Sep 1, 2006 Issue
ADA Releases Standards of Medical Care for Patients with Diabetes [Practice Guidelines]
The American Diabetes Association (ADA) has published a position statement containing evidence-based recommendations for diabetes care, treatment goals, and tools to evaluate the quality of care.
Aug 15, 2006 Issue
CDC Reports on End-stage Renal Disease in Patients with Diabetes [Practice Guidelines]
The Centers for Disease Control and Prevention (CDC) has released a report detailing the incidence of end-stage renal disease (ESRD) in patients with diabetes. Diabetes mellitus is the leading cause of ESRD in the United States, accounting for 44 percent of new cases in 2002.
Insulin detemir is suitable as basal insulin in a basal-bolus regimen. In limited research, it has been shown to cause slightly fewer episodes of minor hypoglycemia and no weight gain in patients with type 1 and 2 diabetes, which is a benefit that must be balanced against its higher price. Insulin d...
Jul 1, 2006 Issue
Antihypertensive Agents for Prevention of Diabetic Nephropathy [Cochrane for Clinicians]
Angiotensin-converting enzyme (ACE) inhibitors are the only antihypertensive agents with proven effectiveness for the primary prevention of diabetic nephropathy (defined as an albumin excretion of less than 30 mg per day on three serial measurements) caused by type 1 or type 2 diabetes. However, ACE...
Jun 15, 2006 Issue
Few Americans with Diabetes Receive Multiple Preventive-Care Services [Practice Guidelines]
Preventive-care services such as annual foot and dilated eye examinations and biannual A1C tests can prevent or delay amputation and blindness from diabetes. The Centers for Disease Control and Prevention (CDC) analyzed data from the Behavioral Risk Factor Surveillance System surveys to determine th...
Exenatide is an injectable treatment for type 2 diabetes. Its use requires patient education and strict monitoring of glucose levels because of the difficulty of its administration; therefore, it may not be a safe or practical option for patients who are not willing or able to administer exenatide correctly.
A report that identifies ways to improve prevention and treatment of cardiovascular disease (CVD) in persons with type 1 diabetes has been released by the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Feb 1, 2006 Issue
Are Alpha-glucosidase Inhibitors Effective for Control of Type 2 Diabetes? [Cochrane for Clinicians]
The use of alpha-glucosidase inhibitors has a modest effect on intermediate diabetes-control endpoints such as postprandial blood glucose, postprandial insulin levels, and A1C levels. There is no evidence, however, of improvement in mortality, morbidity, or quality of life. In comparisons with sulfo...